Industry Strength Score
68/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ARVINAS INC (ARVN) Stock Price & Overview
NASDAQ:ARVN • US04335A1051
Current stock price
10.51 USD
+0.61 (+6.16%)
At close:
10.54 USD
+0.03 (+0.29%)
After Hours:
The current stock price of ARVN is 10.51 USD. Today ARVN is up by 6.16%. In the past month the price decreased by -3.13%. In the past year, price increased by 36.14%.
ARVN Key Statistics
52-Week Range5.9 - 14.51
Current ARVN stock price positioned within its 52-week range.
1-Month Range9.73 - 12.05
Current ARVN stock price positioned within its 1-month range.
- Market Cap
- 672.22M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.28
- Dividend Yield
- N/A
ARVN Stock Performance
Today
+6.16%
1 Week
+0.67%
1 Month
-3.13%
3 Months
-21.45%
Longer-term
6 Months +3.65%
1 Year +36.14%
2 Years -68.29%
3 Years -51.86%
5 Years -85.55%
10 Years N/A
ARVN Stock Chart
ARVN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ARVN. When comparing the yearly performance of all stocks, ARVN turns out to be only a medium performer in the overall market: it outperformed 52.98% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ARVN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ARVN. While ARVN seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ARVN Earnings
On April 30, 2026 ARVN reported an EPS of -1.1 and a revenue of 9.50M. The company missed EPS expectations (-82.67% surprise) and missed revenue expectations (-73.3% surprise).
Next Earnings DateAug 4, 2026
Last Earnings DateApr 30, 2026
PeriodQ4 / 2025
EPS Reported-$1.10
Revenue Reported9.5M
EPS Surprise -82.67%
Revenue Surprise -73.30%
ARVN Forecast & Estimates
26 analysts have analysed ARVN and the average price target is 15.54 USD. This implies a price increase of 47.86% is expected in the next year compared to the current price of 10.51.
For the next year, analysts expect an EPS growth of -173.36% and a revenue growth -68.71% for ARVN
Analysts
Analysts76.15
Price Target15.54 (47.86%)
EPS Next Y-173.36%
Revenue Next Year-68.71%
ARVN Index Membership
ARVN is currently included in the following stock indexes tracked on ChartMill.
ARVN Financial Highlights
Over the last trailing twelve months ARVN reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS increased by 53.79% compared to the year before.
Income Statements
Revenue(TTM)262.60M
Net Income(TTM)-80.80M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.26% | ||
| ROE | -18.62% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-74.6%
Sales Q2Q%-83.95%
EPS 1Y (TTM)53.79%
Revenue 1Y (TTM)-0.3%
ARVN Ownership
Ownership
Inst Owners88.33%
Shares63.96M
Float58.62M
Ins Owners1.29%
Short Float %7.49%
Short Ratio5.07
ARVN Industry Overview
ARVN operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
47%
Outperformed 47% of sub-industries
3 Month Rank
55%
Outperformed 55% of sub-industries
6 Month Rank
41%
Outperformed 41% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 5.2%
- New Lows
- 3%
- Average ROE
- 51.3%
- Average Profit Margin
- 27.9%
- Average Operating Margin
- 37.7%
- Average P/E
- 25.5
- Average Fwd P/E
- 17.7
- Average Debt/Equity
- 1.2
ARVN Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.63 | 883.029B | ||
| JNJ | JOHNSON & JOHNSON | 17.91 | 553.619B | ||
| MRK | MERCK & CO. INC. | 11.43 | 269.662B | ||
| PFE | PFIZER INC | 8.81 | 151.879B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 123.709B | ||
| ZTS | ZOETIS INC | 16.14 | 48.347B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.899B | ||
| VTRS | VIATRIS INC | 6.03 | 17.396B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.39 | 11.171B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.626B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.971B | ||
| CORT | CORCEPT THERAPEUTICS INC | 35.54 | 4.948B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ARVN
Company Profile
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 246 full-time employees. The company went IPO on 2018-09-27. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. The company is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Company Info
IPO: 2018-09-27
ARVINAS INC
5 Science Park
New Haven CONNECTICUT 06511 US
CEO: John Houston
Employees: 246
Phone: 13026365400
ARVINAS INC / ARVN FAQ
What does ARVINAS INC do?
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 246 full-time employees. The company went IPO on 2018-09-27. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. The company is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Can you provide the latest stock price for ARVINAS INC?
The current stock price of ARVN is 10.51 USD. The price increased by 6.16% in the last trading session.
Does ARVN stock pay dividends?
ARVN does not pay a dividend.
What is the ChartMill rating of ARVINAS INC stock?
ARVN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is ARVINAS INC (ARVN) stock traded?
ARVN stock is listed on the Nasdaq exchange.
What do analysts say about ARVINAS INC (ARVN) stock?
26 analysts have analysed ARVN and the average price target is 15.54 USD. This implies a price increase of 47.86% is expected in the next year compared to the current price of 10.51.
What is the market capitalization of ARVN stock?
ARVINAS INC (ARVN) has a market capitalization of 672.22M USD. This makes ARVN a Small Cap stock.